Kura Oncology (KURA)
(Delayed Data from NSDQ)
$18.97 USD
-0.15 (-0.78%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.95 -0.02 (-0.11%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 121 - 140 ( 263 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 7122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; In These Markets, Cash Strong Should Be Enough, But There''s More; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
AACR Preclinical Data Point to New Tipifarnib Path; KURRENT-LUNG Phase 1 Trial to Initiate in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Upcoming Data to Bring Focus During Volatile Markets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department